NAGE

ChromaDex Corp.

3.24^post−$0.23 (−6.63%)at close −$0.06 (−1.70%)

tap the star to start your desk

as of 20:27:36 UTCnext report Nov 5 · 92d

Performance

3M−30.18%

Relationships

6 ties · EDGAR · select for source

NAGE

NAGE buys fromNAGE sells to

what am I seeing?

Nodes sit closer to NAGE when the tie is more firmly disclosed — a named revenue weight first, then high-confidence ties, then the rest. A node's glow tracks its move today: it lifts (green) when up, sinks (red) when down, and brightens with the size. Select any node for the filing sentence behind the tie.

etf exposure · n-port

IWM0.01%

Earnings

reporting now

Reported yesterday, after the close · Q2 FY26The move it made lands here once the session that absorbs it closes.

has moved

±20.2%

per session, last 8 reports

Open the Earnings Roomthe report · expected movement · blast radius · the record

Earnings

loading…

Event sensitivity

computed

CPIconsumer pricesup 4 of 8±2.8%0.9×

PPIproducer pricesup 2 of 8±2.6%0.9×

FOMCrate decisionup 7 of 24±2.6%0.9×

PCEpersonal income & outlaysup 8 of 17±2.5%0.8×

CPROFcorporate profitsup 4 of 10±2.1%0.7×

GDPgross domestic productup 6 of 17±1.8%0.6×

NFPjobs reportup 1 of 7±1.0%0.3×

How NAGE has moved on past release days vs its typical ±3.0% day, and how often it closed up. Computed from daily closes — not a forecast.

Event sensitivity

loading…

News

13 stories · wire

NAGE9hNiagen Bioscience, Inc. — 8-K filed · Item 2.02, 7.01, 9.01 · SEC

News

loading…

Overview

Pharmaceutical Products

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

sector: Manufacturing
chief executive: Robert N. Fried
employees: 120
headquarters: California · United States of America
listed: Nasdaq
web: chromadex.com

Overview

loading…